Evidence map›Paper›PMID 29484327›Full record

ArticleChemical communications (Cambridge, England)2018

The effect of geometric isomerism on the anticancer activity of the monofunctional platinum complex trans-[Pt(NH

Wen Zhou, Mohammad Almeqdadi, Michael E Xifaras, Imogen A Riddell, Ömer H Yilmaz, Stephen J Lippard

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Chemical communications (Cambridge, England), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.5field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 27 citations in OpenAlex.

  1. Article
  2. Article
  3. Monofunctional Platinum(II) Anticancer Agents.Pharmaceuticals (Basel, Switzerland) · 2021
    Review
  4. Arsenoplatin-1 Is a Dual Pharmacophore Anticancer Agent.Journal of the American Chemical Society · 2019
    Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Wen ZhouDepartment of Chemistry, Massachusetts Institute of Technology, Cambridge, MA 02139, USA. lippard@mit.edu and The Koch Institute for Integrative Cancer Research, Massachusetts Institute of Tehcnology, Cambridge, MA 02139, USA. ohyilmaz@mit.edu.ORCID http://orcid.org/0000-0001-8455-6011
Mohammad AlmeqdadiThe Koch Institute for Integrative Cancer Research, Massachusetts Institute of Tehcnology, Cambridge, MA 02139, USA. ohyilmaz@mit.edu.ORCID http://orcid.org/0000-0002-5503-2371
Michael E XifarasThe Koch Institute for Integrative Cancer Research, Massachusetts Institute of Tehcnology, Cambridge, MA 02139, USA. ohyilmaz@mit.edu.ORCID http://orcid.org/0000-0001-9973-5733
Imogen A RiddellDepartment of Chemistry, Massachusetts Institute of Technology, Cambridge, MA 02139, USA. lippard@mit.edu.ORCID http://orcid.org/0000-0002-6801-0198
Ömer H YilmazThe Koch Institute for Integrative Cancer Research, Massachusetts Institute of Tehcnology, Cambridge, MA 02139, USA. ohyilmaz@mit.edu.
Stephen J LippardDepartment of Chemistry, Massachusetts Institute of Technology, Cambridge, MA 02139, USA. lippard@mit.edu.ORCID http://orcid.org/0000-0002-2693-4982
Koch Institute for Integrative Cancer Research At MIT · USMassachusetts Institute of Technology · US

Funding

Understanding and Improving Platinum Anticancer DrugsR01CA034992 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI YILMAZ, OMER · 1985 to 2018
$6.8M
CHEMISTRY AND BIOLOGY OF PLATINUM ANTICANCER DRUGSR37CA034992 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI LIPPARD, STEPHEN J. · 1990 to 2008
$5.7M
Dietary control of stem cells in physiology and cancerR01CA211184 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI YILMAZ, OMER · 2017 to 2021
$2.0M
Regulation of the Intestinal Stem Cell Niche in AgingR00AG045144 · NIA · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI YILMAZ, OMER · 2014 to 2016
$740k
Regulation of the Intestinal Stem Cell Niche in AgingK99AG045144 · NIA · WHITEHEAD INSTITUTE FOR BIOMEDICAL RES · PI YILMAZ, OMER · 2013 to 2014
$275k
NCI NIH HHS R01 CA034992NCI NIH HHS R01 CA211184NCI NIH HHS R37 CA034992NIA NIH HHS K99 AG045144NIA NIH HHS R00 AG045144
6 · The paper itself

Abstract

A trans-DDP based monofunctional phenanthridine Pt(ii) complex was synthesized and characterized. Its anticancer activity was studied in vitro on a panel of human cancer cell lines and mouse intestinal cancer organoids. This complex displays significant antitumor properties, with a different spectrum of activity than that of classic bifunctional cross-linking agents like cisplatin.

Indexed as

Antineoplastic AgentsCell Line, TumorCell ProliferationCell SurvivalCrystallography, X-RayDose-Response Relationship, DrugDrug Screening Assays, AntitumorHumansIsomerismModels, MolecularMolecular StructureOrganoplatinum CompoundsStructure-Activity RelationshipAntineoplastic AgentsOrganoplatinum Compounds

Identifiers

PMID29484327
PMCPMC5988251
OpenAlexW2788989835

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.